Pharmaceutical

Roche’s Columvi receives marketing approval in Europe

The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.

Jul 11, 2023 - 20:00
Roche’s Columvi receives marketing approval in Europe
The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.
Read the original article

Tags:

Previous Article

Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

Next Article

Iovance looks to advance its non-small cell lung cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery

STAT+: For-profit biomedical institute, backed by billi...

Jan 14, 2024

Private equity deals in pharmaceutical in Middle East and Africa increased in Q2 2023

Private equity deals in pharmaceutical in Middle East a...

Jul 25, 2023

STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

STAT+: Moonlake’s less-than-transparent data disclosure...

Jun 28, 2023